How often do you feel agitated, easily upset, and nervous between meals? How often do you depend on coffee to keep yourself going? How often do you have difficulty concentrating before eating? Inflammation is an essential reaction of the human body. It’s triggered by the immune system to protect us from injury, infection, and/or illness. However, what happens if there is too much inflammation in the human body? And, what happens if there is too much inflammation in the brain?
Neuroinflammation can cause a variety of health issues, such as anxiety, stress, depression, brain fog, fatigue, and even lethargy, among other well-known symptoms. Fortunately, there is one natural remedy that can help tremendously reduce inflammation and improve brain function. According to research studies, curcumin can help combat neuroinflammation. The purpose of the article below is to discuss the anti-inflammatory effects of curcumin in microglia, brain health, and wellness.
Lipoteichoic acid (LTA) induces neuroinflammatory molecules, contributing to the pathogenesis of neurodegenerative diseases. Therefore, suppression of neuroinflammatory molecules could be developed as a therapeutic method. Although previous data supports an immune-modulating effect of curcumin, the underlying signaling pathways are largely unidentified. Here, we investigated curcumin’s anti-neuroinflammatory properties in LTA-stimulated BV-2 microglial cells. Inflammatory cytokine tumor necrosis factor-? [TNF-?, prostaglandin E2 (PGE2), and Nitric Oxide (NO] secretion in LTA-induced microglial cells were inhibited by curcumin. Curcumin also inhibited LTA-induced inducible NO synthases (iNOS) and cyclooxygenase-2 (COX-2) expression. Subsequently, our mechanistic studies revealed that curcumin inhibited LTA-induced phosphorylation of mitogen-activated protein kinase (MAPK) including ERK, p38, Akt, and translocation of NF-?B. Furthermore, curcumin induced hemeoxygenase (HO)-1HO-1 and nuclear factor erythroid 2-related factor 2 (Nrf-2) expression in microglial cells. Inhibition of HO-1 reversed the inhibition effect of HO-1 on inflammatory mediators released in LTA-stimulated microglial cells. Taken together, our results suggest that curcumin could be a potential therapeutic agent for the treatment of neurodegenerative disorders via suppressing neuroinflammatory responses. Keywords: curcumin, neuroinflammation, TLR2, HO-1, microglial cells
Chronic neuroinflammation plays an important role in various neurodegenerative diseases, including AD, Parkinson’s disease (PD), Huntington’s disease (HD), stroke, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) (Spangenberg and Green, 2017). Neuroinflammation is interceded by the activation of microglia, the prime effector cells and resident immune cells of the CNS (Nakagawa and Chiba, 2015). Microglial cells can be activated in response to neuronal death or neuronal damage induced by neuroinflammatory responses or by extracellular toxins, such as bacteria and pathogens (Larochelle et al., 2015). In neuroinflammation, activated microglia releases various kinds of cytokines, chemokines, reactive oxygen species, and reactive nitrogen species for the development and maintenance of inflammatory responses (Moss and Bates, 2001). Excessive production of these inflammatory mediators could cause neuronal damage and death. Accumulated evidence suggests that control of microglial activation could attenuate the severity of neurodegenerative disease (Perry et al., 2010). Therefore, the development of anti-neuro-inflammatory agents for the inhibition of microglial activation could be beneficial for the treatment of neurodegenerative diseases.
Microglia express pattern recognition receptors (PRR) that can bind to pattern-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA), respectively (Jack et al., 2005). TLRs, a major class of PRRs, play a crucial role in host defense by inducing innate immune responses. Increasingly, studies have indicated that TLR2 agonist LTA is involved in the pathogenesis of CNS infectious diseases and can induce neuronal damage (Neher et al., 2011). Inhibition of TLR2 activation attenuates microglial cell activation and amyloid ? accumulation in the brain (McDonald et al., 2016; Hossain et al., 2017). Signal transduction via TLR2 is mediated by different adaptor proteins, including MyD88, which promotes downstream signaling via MAPK and NF-?B activation leading to the expression of inflammatory mediators (Larochelle et al., 2015).
Inflammatory and oxidative molecules are very potent activators of Keap-Nrf2 (NF-E2-related factor 2), which induces the expression of Phase II detoxification enzymes to adapt to the oxidative stress condition (Rojo et al., 2010). Usually, Nrf2 acts in an inactive form. Upon stimulation, Nrf2 separates from Keap1 and translocates into the nucleus, where it binds to the antioxidant response element (ARE) to activate the transcription of antioxidant genes for cytoprotection (Ma, 2013; Cho et al., 2015). One of the Nrf2-regulated genes is heme oxygenase-1 (HO-1), which has an ARE sequence in its promoter region. Recently, HO-1 has been reported to be a predominant factor in controlling oxidative stress and inflammatory responses in neurodegenerative diseases (Schipper et al., 2009). HO-1 is the first inducible rate-limiting enzyme in the degradation of heme into by-products. HO-1 may provide neuroprotection or neurotoxic effect because of the balance between the beneficial and toxic effects of heme and heme products (Mancuso et al., 2010). One by-product of HO-1, Bilirubin, has been demonstrated to protect neurons from oxidative stress in vivo and in vitro. Bilirubin can be oxidized to biliverdin by scavenging peroxyl radicals (Chen, 2014). It has been suggested that HO-1, biliverdin, and CO have anti-inflammatory properties (Jazwa and Cuadrado, 2010). Another study has suggested that mice lacking HO-1 were vulnerable to pro-inflammatory stimuli and developed chronic inflammation due to reduced iron levels (Chora et al., 2007). Furthermore, a recent study suggested that the up-regulation of the Nrf2 and HO-1 pathways significantly inhibited the inflammatory reaction in activated microglia (Kim et al., 2016). Nrf2 inhibited microglial hyperactivation by suppressing p38 MAPK and the NF-?B signaling pathway (Kim B.W. et al., 2013). Knockdown of Nrf2 in mice was shown to be hypersensitive to neuroinflammation, as indicated by an increase in the inflammatory markers iNOS, IL-6, and TNF-? (Rojo et al., 2010). Consequently, Nrf2 and HO-1 have been considered as important therapeutic targets for neurodegenerative diseases (Koh et al., 2011; Zhang et al., 2014).
Curcumin, the main curcuminoid isolated from Curcuma longa L. (turmeric) has been used for centuries in Southeast Asia both as a medicinal remedy and as food (Kunnumakkara et al., 2017). Curcumin, demethoxycurcumin, bisdemethoxycurcumin, ar-turmerone, ?-turmerone, and ?-turmerone are the major bioactive compounds found in C. longa. In modern pharmacological studies, C. longa constituents, particularly curcumin, have shown promising pharmacological activities due to its anti-neuroinflammatory, neuroprotective, chemopreventive, immunomodulatory, and potentially chemotherapeutic effects (Garcia-Alloza et al., 2007; Zhou et al., 2017). A previous study showed that curcumin inhibited LPS-induced inflammatory responses in RAW264.7 macrophages, suggesting a potential role of curcumin in anti-Gram-negative bacterial infection (Zhou et al., 2017) and both in vivo and in vitro research have shown that curcumin exhibits anti-inflammatory effects (Garcia-Alloza et al., 2007; Prakobwong et al., 2011; Parada et al., 2015; Li et al., 2016). Furthermore, curcumin has also been reported to promote the development of the M2 microglial phenotype in an HO-1-dependent manner and reduce iNOS induction, protecting microglial cells against oxidative stress (Parada et al., 2015). In the present study, we investigated whether curcumin could affect LTA-induced microglial activation. The TLR2 ligand LTA is a major constituent of the cell wall of Gram-positive bacteria. We show that curcumin exhibits anti-inflammatory and antioxidant effects in LTA-stimulated BV2 microglia through activation of HO-1/Nrf2/ARE cytoprotective mechanisms.
Curcumin and other reagents were purchased from Sigma (C7727, >80%, St. Louis, MO, United States). Protoporphyrin IX (SnPP) and antibodies directed against HO-1 (sc-390991) – Nrf2 (sc-722), TATA-binding protein (TBP; sc-74595), ?-tubulin (sc-134237), and ?-actin (sc-130065) – were purchased from Santa Cruz Biotechnology, Inc., (Dallas, TX, United States). Antibodies directed against iNOS (13120) – phosphorylated (p)-MAPK (9910s), MAPK (9926), protein kinase B (Akt; 4685), p-Akt (13038), and an NF-?B pathway kit (9936) – were purchased from Cell Signaling Technology, Inc., (Danvers, MA, United States). LTA was obtained from InvivoGen (tlrl-pslta,Toulouse, France). Additionally, JNK inhibitor (JNK inhibitor II; 420119), Akt inhibitor (wortmannin; 12-338), ERK inhibitor (PD98059, 513000), and p38 inhibitor (SB230580, 559395) were purchased from EMD Millipore (Billerica, MA, United States). The cell culture medium, DMEM, and fetal bovine serum (FBS) were purchased from Gibco BRL (now Invitrogen Corporation, Carlsbad, CA, United States).
Mouse BV-2 microglial cells were purchased from ATCC. Cells were cultured in DMEM supplemented with 10% heat-inactivated FBS and 0.1% penicillin-streptomycin (BioSource International, Camarillo, CA, United States) at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
The cytotoxicity of curcumin was assessed using a microculture [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT)-based colorimetric assay. Cells were incubated in 24-well plates at a density of 5 × 105 cells per well. The MTT solution (5 ml of 5 mg/ml) was added to each well (final concentration 62.5 mg/ml). After incubation for 3 h at 37°C in 5% CO2, the supernatant was removed and the formazan crystals produced in viable cells were solubilized with 150 ml of dimethylsulfoxide (DMSO). The absorbance of each well was then read at 570 nm using a microplate reader (Wallac 1420; PerkinElmer, Inc., Boston, MA, United States).
NO synthesis in cell cultures was measured by the Griess method with microplate. To measure nitrite, 100-?l aliquots were removed from the conditioned medium and incubated with an equal volume of the Griess reagent [1% sulfanilamide/0.1%N-(1-naphthyl)-ethylenediaminedihydrochloride/2.5% H3PO4] at room temperature for 10 min. The nitrite concentration was determined by measuring the absorbance at 540 nm with a Vmax 96-well microplate spectrophotometer (Molecular Devices, Menlo Park, CA, United States). Sodium nitrite was used as a standard.
The cells were incubated first with various concentrations of curcumin for 1 h and then with LTA for 16 h. Following 24 h incubation, TNF-? and PGE2 levels were quantified in the culture media using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, United States) according to the manufacturer’s instructions.
BV-2 microglial cells were washed three times with cold PBS and collected in 3000 ?l PBS using centrifugation at 800 ×g for 5 min (4°C). The cell pellets were suspended in buffer A [10 mM HEPES-KOH (pH 7.9); 1.5 mM MgCl2; 10 mM KCl; 0.5 mM dithiothreitol (DTT); 0.2 mM protease inhibitor (PI)] and incubated for 5 min on ice. Buffer B [10 mM HEPES-KOH (pH 7.9); 1.5 mM MgCl2; 420 mM NaCl; 0.2 mM EDTA; glycerol 25% v/v; 0.1 mM DTT; 0.2 mM PI] was added to the cell extract and was incubated on ice for 5 min prior to centrifugation at 11,000 ×g for 1 min at 4°C. Nuclear proteins were extracted with the addition of complete lysis buffer B [10 mM HEPES-KOH (pH 7.9); 1.5 mM MgCl2; 10 mM KCl; 0.5 mM DTT; 0.2 mM PI; 25% (w/v) glycerin; 420 mM NaCl; 0.2 mM EDTA] for 30 min at 4°C with occasional vortexing. Following centrifugation at 11,000 ×g for 5 min at 4°C, the supernatants were collected and stored at -70°C.
BV-2 cells were harvested in an ice-cold lysis buffer (1% Triton X-100; 1% deoxycholate; 0.1% sodium dodecyl sulfate). The protein content of the cell lysates was subsequently determined using Bradford reagent (Bio-Rad Protein Assay Kit I5000001; Bio-Rad Laboratories, Inc., Hercules, CA, United States). Total proteins in each sample (50 ?g) were separated by 7.5% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Following blocking of the non-specific binding sites with 5% non-fat milk at room temperature for 30 min, the membranes were incubated with primary antibodies directed against iNOS (1:500), p-Akt (1:1,000), p-MAPK (1:1,000), MAPK (1:1,000), p-p65, p65 (1:500), p-I?B?, I?B? (1:1,000), HO-1 (1:1,000), Nrf2 (1:1,000), TBP (1:3,000), ? (1:1,000), HO-1 (1:1.0), and actin (1:3,000) for 16 h at 4°C. This was followed by incubation with horseradish peroxidase-conjugated anti-rabbit (sc-2768; 1:5,000) or anti-mouse (sc-2371; 1:5,000) secondary antibodies (Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. Tubulin was used as the loading control for each lane. The proteins were visualized using an enhanced chemiluminescence detection kit (GE Healthcare, Chicago, IL, United States). Following washing with PBS with Tween-20, the protein bands were visualized using the Gel Docsed as the loading control for each lane. The proteins were visualized using a Quant 350 analyzer (GE Healthcare).
Total RNA was isolated from cells using an RNA spin miniRNA isolation kit (GE Healthcare, Uppsala, Sweden) according to the manufacturer’s instructions. cDNA was synthesized from 1 ?g of total RNA using Maxime RT PreMix (Takara, Gyeonggi-do, Japan) and anchored oligo-dT15-primers. Real-time PCR was performed using a Chromo4TM instrument (Bio-Rad) and SYBR Green Master Mix (Applied Biosystems, Foster City, CA, United States). Relative amounts of target mRNA were determined using the comparative threshold (Ct) method by normalizing target mRNA Ct values to those for ?-actin (Ct). Prime sequences used in the study were shown in Table ?1.
Data are expressed as the mean (standard deviation, SD). Each experiment was repeated at least three times. Statistical analysis was performed using the Statistical Package for GraphPad Prism software (version 16.0) to determine significant differences. We used either Student’s t-test or one-way analysis of variance (ANOVA) followed by Dunn’s post hoc tests for analyses. P-values < 0.05 were considered statistically significant.
Cell viability experiments were carried out to determine whether concentrations of curcumin used in this study affected the viability of BV2 microglia. Figure ?1 shows that curcumin at the concentration range of 5–20 ?M, together with or without 5 ?g/ml LTA, did not produce cytotoxicity in BV2 microglia. Therefore, we used these concentrations of curcumin for further study.
To investigate the effects of curcumin on the secretion of inflammatory cytokines, BV2 cells were treated with LTA in the presence and absence of curcumin for 24 h. Curcumin was not removed before LTA addition. Release of NO, PGE2, and TNF-? were significantly and dose-dependently reduced by curcumin (Figures 2A–C). Furthermore, LTA increased the mRNA expression of iNOS and COX-2. Incubation with curcumin suppressed the mRNA expression of COX-2 and iNOS in BV2 microglial cells stimulated by LTA in a concentration-dependent manner (Figures 2D, E).
The genes encoding inflammatory protein expression in response to microglial activation were under the transcription control of NF-?B. Therefore, we examined the effect of curcumin on the activation of NF-?B in LTA-stimulated microglial cells. The results showed that LTA induced a characteristic increase in the phosphorylation of I?B?. Following pre-treatment with curcumin, levels of p-I?B? were significantly reduced in a concentration-dependent manner (Figure ?3 and Supplementary Figure S1). Consistently, the nuclear translocation of the NF-?B p65 subunit induced by LTA was also attenuated by pre-treatment with curcumin. Taken together, curcumin likely attenuates the expression of neuroinflammatory molecules by suppressing the nuclear translocation and activation of NF-?B. Quantification with statistical analysis was provided as supporting data.
Apart from NF-?B, MAPKs are also upstream modulators of neuroinflammatory molecules in microglial cells. Previous studies showed that curcumin antagonized LPS-induced MAPKs phosphorylation in microphage (Yang et al., 2008; Kunnumakkara et al., 2017). To investigate whether curcumin inhibits neuroinflammation through regulating MAPKs, we examined its effects on LTA-induced MAPK phosphorylation. BV-2 microglial cells were pre-treated with different concentrations of curcumin for 3 h and were then stimulated with LTA for 1 h. As shown in Figure ?4A and Supplementary Figure S2, curcumin inhibited LTA-induced ERK, p38, and Akt phosphorylation. However, up to 20 ?M curcumin did not affect LTA-induced JNK phosphorylation. MAPKs pathway has been reported to mediate the production of cytokines, chemokine, and other neuroinflammatory molecules. Therefore, we next investigated the role of ERK, p38, JNK, and Akt in BV2 cells’ neuroinflammatory molecule production using the ERK, p38, JNK, and Akt inhibitors. However, only the p38 inhibitor SB203580 significantly decreased LTA-induced release of NO and mRNA expression levels of iNOS (Figures 4B, C). Although phosphorylation of JNK was not inhibited by curcumin, the JNK inhibitor II significantly inhibited LTA-induced NO release (Figure ?4B). The results suggest that MAPKs’ signaling pathways are involved in curcumin’s anti-neuroinflammatory effects in LTA-stimulated microglial. Quantification with statistical analysis is provided as supporting data.
HO-1 acts as an anti-inflammatory and antioxidant modulator in microglia (Schipper et al., 2009). Western blot and RT-PCR analyses showed that curcumin upregulated HO-1 expression at the protein and mRNA levels, as shown in Figures 5A–D and Supplementary Figure S3. The expression of HO-1 mRNA and protein was maximally increased in BV-2 microglial cells treated with 20?M curcumin for 4 h and 8 h respectively. Furthermore, curcumin increased Nrf2 nuclear translocation within 1 h and prolonged its nuclear translocation state to 2 h (Figures 5E, F and Supplementary Figure S3). Next, we investigated whether curcumin-induced HO-1 mediated an anti-neuroinflammatory response in LTA-stimulated BV-2 microglial cells. We treated cells with the HO-1 inhibitor SnPP. We then evaluated curcumin’s effect on LTA-induced NO and TNF-? release. Treatment with SnPP significantly suppressed curcumin-mediated inhibition of NO and TNF-a release (Figures 5G, H). Taken together, these results reveal that curcumin-dependent HO-1 and Nrf-2 signal activation plays a crucial role in downregulating neuroinflammatory responses. Quantification with statistical analysis is provided as supporting data.
Microglia, the major resident macrophages of the CNS, has been reported to be the main effector cells in mediating neuroinflammation and selective neuronal death (Perry et al., 2010). Microglial cells increase the production of neuroinflammatory molecules after exposure to activators such as LPS and LTA via their surface receptors, TLR4 and TLR2, respectively (Perry and Holmes, 2014; Hossain et al., 2017). Increased expression and activation of TLR2 is associated with the progression of neurodegenerative diseases, such as PD and dementia (Dzamko et al., 2017). For example, activation of TLR2 could upregulate ?-synuclein in PD brains and play important roles in the pathogenesis of PD brains (Roodveldt et al., 2013). In addition, Kim C. et al. (2013) also showed that neurodegeneration was attenuated by either knockout or knockdown of TLR2 in rodent PD models. Thus, controlling TLR2-mediated microglia activation and neurotoxicity has been suggested as an important therapeutic approach to treating neurodegenerative diseases. A potential agent in this process could be curcumin, which has been shown to exert neuro-protective and anti-inflammatory effects in various experiment models (Parada et al., 2015; Li et al., 2016). Curcumin is a highly lipophilic natural compound. A previous study has well demonstrated that curcumin is able to cross the blood–brain barrier and that it is mainly concentrated in the hippocampus in the brain (Tsai et al., 2011). Some studies reported that curcumin inhibited HIV-1 gp120-induced neuronal damage and provided anti-neuroinflammatory effects in LPS-induced microglia (Gong et al., 2012). This protective effect of curcumin seems to be dependent on its anti-inflammatory actions. Curcumin could protect neurons against microglia-mediated neurotoxicity while becoming inefficient under microglia-depleted conditions (Park et al., 2001; Yang et al., 2008; Parada et al., 2015). Similar studies in peripheral cells also showed the anti-inflammatory effects of curcumin. Using RAW 264.7 murine macrophages, studies have shown that curcumin inhibited PGE2, NO, and TNF-? release following LPS stimulation (Pae et al., 2008). However, the effects of curcumin on TLR2-induced neuroinflammation in microglial cells are not fully understood.
Regulation of the signaling pathways in activated microglia is important in maintaining CNS homeostasis because deregulated neuroinflammatory responses can result in the death of adjacent neurons through the release of inflammatory molecules, such as cytokines, chemokines, NO, and ROS (Perry and Holmes, 2014; Spangenberg and Green, 2017). For example, excessive NO synthesis under endotoxins results in the formation of reactive nitrogen species and neuronal cell death (Perry et al., 2010). PGE2 has also been shown to contribute to neuronal death through activation of the MAPK/ERK pathway in microglia (Xia et al., 2015). In this present study, we showed that curcumin inhibited the secretion of inflammatory mediators TNF-?, NO, and PGE2, and expression of iNOS and COX-2 in BV2 microglia stimulated with LTA. We further showed that curcumin attenuated these effects of LTA without altering cell survival, suggesting that curcumin is safe and could be considered as a potential therapeutic agent in neuroinflammation.
NF-?B is the main transcription factor which plays critical roles in regulating redox homeostasis. NF-?B is considered the master regulator of microglial inflammatory responses to neuronal injury (Acharyya et al., 2007). Recent studies showed that NF-?B activation controlled the expression of inflammatory molecules, such as NO, PGE2, and TNF-?, and IL-1b production (Acharyya et al., 2007). Therefore, modulation of NF-?B activation is considered a critical way to control microglial activation. The activation of the NF-?B signaling pathway is mediated by the I?B protein. The phosphorylation of I?B results in NF-?B dissociation, which leads to the induction of inflammatory mediators. In this study, it was shown that curcumin produced dual inhibition of phosphorylation and degradation of I?B?, as well as nuclear translocation of p65, suggesting that this agent could stabilize NF-?B in the microglial cytoplasm following stimulation with LTA in BV-2 microglial cells.
In mammalian cells, MAPKs signaling pathways, including ERK, JNK, and p38, contribute to the production of a wide variety of neuroinflammatory mediators (Chantong et al., 2014). In this present study, pre-treatment with curcumin decreased the phosphorylation of p38 and ERK. Furthermore, the p38 inhibitor SB203580 significantly reduced the secretion of NO and the mRNA expression of the key pro-inflammatory gene, iNOS. These results suggested that curcumin initiated the anti-neuroinflammatory effects in LTA-stimulated BV-2 microglial cells, partially through inhibition of p38 MAPK activation. The PI3K/Akt-dependent signaling pathway promotes inflammatory responses in microglia. The involvement of the Akt pathway has been shown in the expression of inflammatory mediators in microglia through the activation of NF-?B in microglia (Lo et al., 2015). Curcumin suppressed the phosphorylated Akt, the downstream target of PI3K. However, the PI3K inhibitor wortmannin did not show any inhibitory effect on the secretion of NO or the mRNA expression of iNOS. Taken together, these data suggest that the anti-neuroinflammatory effect of curcumin occurs mainly through inhibiting the NF-?B and MAPKs signaling.
We also identified the intracellular pathway that negatively regulates the inflammatory-molecule expression in microglial cells. Nrf2 is a redox-sensitive transcription factor that regulates microglial inflammatory responses to brain infections. The effect of Nrf2 has been described in different in vivo models where knockdown of Nrf2 in mice enhanced vulnerability to asthma or emphysema (Ma, 2013). Moreover, the TLR2/TLR4 agonist promoted inflammatory responses in Nrf2 KO mice compared to WT mice (Kong et al., 2011). In the current study, we showed that curcumin increased the expression of Nrf2 and its downstream protein HO-1. HO-1 is a key signaling molecule implicated in the regulation of inflammatory and oxidative responses. The HO-1 gene has an ARE sequence in its promoter region, which is a binding site for the transcription factor Nrf2. Several studies have proposed that NF-?B interrupts the Nrf-2-ARE signaling pathway because many compounds that induced HO-1 and Nrf2 signaling incidentally repressed NF-?B activation (Li et al., 2016). HO-1 expression was essential for the microglial specific cytoprotective effect (Parada et al., 2015). Several studies have also shown an inverse correlation between HO-1 and inflammatory mediator secretion (Chora et al., 2007; Parada et al., 2015). In agreement, we observed that curcumin alone induced the expression of HO-1 in microglial cells. Furthermore, the HO-1 inhibitor abrogated curcumin anti-inflammatory effect in BV-2 microglial cells.
This study demonstrated that curcumin had anti-inflammatory activity in LTA-stimulated microglial cells that may through inhibiting NF-?B and p38 MAPK activation, and may induce the expression of Nrf2 and HO-1 (Figure ?6). Furthermore, curcumin does not have cytotoxic effects in BV-2 microglial cells at its anti-inflammatory dose. Curcumin may have therapeutic potential for some neuroinflammation-associated disorders caused by Gram-positive bacteria.
Curcumin, or turmeric, is a powerful anti-inflammatory which has been demonstrated to have many health benefits. Regarded as an antioxidant with anti-cancer, antidepressant, and anti-aging properties, curcumin can do much more than heal wounds and enhance memory. According to research studies, curcumin or turmeric can help reduce neuroinflammation or brain inflammation. This powerful anti-inflammatory can block the production of proinflammatory cytokines and promote overall well-being. – Dr. Alex Jimenez D.C., C.C.S.T. Insight
The following Neurotransmitter Assessment Form can be filled out and presented to Dr. Alex Jimenez. Symptoms listed on this form are not intended to be utilized as a diagnosis of any type of disease, condition, or any other type of health issue.
In honor of Governor Abbott’s proclamation, October is Chiropractic Health Month. Learn more about the proposal.
How often do you feel agitated, easily upset, and nervous between meals? How often do you depend on coffee to keep yourself going? How often do you have difficulty concentrating before eating? Inflammation is an important response of the human body. It’s activated by the immune system to guard us against injury, infection, and/or illness. However, what happens if there is too much inflammation in the human body? And, what happens if there is too much inflammation in the brain?
Brain inflammation can cause a variety of health issues, such as anxiety, stress, depression, brain fog, fatigue, and even lethargy, among other common symptoms. Fortunately, there is one natural remedy that can help greatly reduce neuroinflammation and improve brain function. According to research studies, curcumin can combat brain inflammation. The purpose of the article above was to discuss the anti-inflammatory effects of curcumin in microglia and brain well-being
The following article has been referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic, musculoskeletal and nervous health issues or functional medicine articles, topics, and discussions. We use functional health protocols to treat injuries or disorders of the musculoskeletal system. To further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez or contact us at 915-850-0900 .
Curated by Dr. Alex Jimenez
1. Acharyya S., Villalta S. A., Bakkar N., Bupha-Intr T., Janssen P. M., Carathers M., et al. (2007). Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 117 889–901. 10.1172/JCI30556 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Chantong B., Kratschmar D. V., Lister A., Odermatt A. (2014). Dibutyltin promotes oxidative stress and increases inflammatory mediators in BV-2 microglia cells. Toxicol. Lett. 230 177–187. 10.1016/j.toxlet.2014.03.001 [PubMed] [CrossRef] [Google Scholar]
3. Chen J. (2014). Heme oxygenase in neuroprotection: from mechanisms to therapeutic implications. Rev. Neurosci. 25 269–280. 10.1515/revneuro-2013-0046 [PubMed] [CrossRef] [Google Scholar]
4. Cho H., Hartsock M. J., Xu Z., He M., Duh E. J. (2015). Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. J. Neuroinflamm. 12:239. 10.1186/s12974-015-0452-z [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Chora A. A., Fontoura P., Cunha A., Pais T. F., Cardoso S., Ho P. P., et al. (2007). Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 117 438–447. 10.1172/JCI28844 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Dzamko N., Gysbers A., Perera G., Bahar A., Shankar A., Gao J., et al. (2017). Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 133 303–319. 10.1007/s00401-016-1648-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Garcia-Alloza M., Borrelli L. A., Rozkalne A., Hyman B. T., Bacskai B. J. (2007). Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 102 1095–1104. 10.1111/j.1471-4159.2007.04613.x [PubMed] [CrossRef] [Google Scholar]
8. Gong Z., Yang L., Tang H., Pan R., Xie S., Guo L., et al. (2012). Protective effects of curcumin against human immunodeficiency virus 1 gp120 V3 loop-induced neuronal injury in rats. Neural Regen. Res. 7 171–175. 10.3969/j.issn.1673-5374.2012.03.002 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Hossain M. J., Tanasescu R., Gran B. (2017). Innate immune regulation of autoimmunity in multiple sclerosis: focus on the role of Toll-like receptor 2. J. Neuroimmunol. 304 11–20. 10.1016/j.jneuroim.2016.12.004 [PubMed] [CrossRef] [Google Scholar]
10. Jack C. S., Arbour N., Manusow J., Montgrain V., Blain M., McCrea E., et al. (2005). TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 175 4320–4330. 10.4049/jimmunol.175.7.4320 [PubMed] [CrossRef] [Google Scholar]
11. Jazwa A., Cuadrado A. (2010). Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr. Drug Targets 11 1517–1531. 10.2174/1389450111009011517 [PubMed] [CrossRef] [Google Scholar]
12. Kim B. W., Koppula S., Hong S. S., Jeon S. B., Kwon J. H., Hwang B. Y., et al. (2013). Regulation of microglia activity by glaucocalyxin-A: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-kappaB and p38 MAPK signaling pathways. PLoS One 8:e55792. 10.1371/journal.pone.0055792 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Kim C., Ho D. H., Suk J. E., You S., Michael S., Kang J., et al. (2013). Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4:1562. 10.1038/ncomms2534 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Kim H. J., Kang C. H., Jayasooriya R. G., Dilshara M. G., Lee S., Choi Y. H., et al. (2016). Hydrangenol inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglial cells by suppressing the NF-kappaB pathway and activating the Nrf2-mediated HO-1 pathway. Int. Immunopharmacol. 35 61–69. 10.1016/j.intimp.2016.03.022 [PubMed] [CrossRef] [Google Scholar]
15. Koh K., Kim J., Jang Y. J., Yoon K., Cha Y., Lee H. J., et al. (2011). Transcription factor Nrf2 suppresses LPS-induced hyperactivation of BV-2 microglial cells. J. Neuroimmunol. 233 160–167. 10.1016/j.jneuroim.2011.01.004 [PubMed] [CrossRef] [Google Scholar]
16. Kong X., Thimmulappa R., Craciun F., Harvey C., Singh A., Kombairaju P., et al. (2011). Enhancing Nrf2 pathway by disruption of Keap1 in myeloid leukocytes protects against sepsis. Am. J. Respir. Crit. Care Med. 184 928–938. 10.1164/rccm.201102-0271OC [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Kunnumakkara A. B., Bordoloi D., Padmavathi G., Monisha J., Roy N. K., Prasad S., et al. (2017). Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br. J. Pharmacol. 174 1325–1348. 10.1111/bph.13621 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Larochelle A., Bellavance M. A., Rivest S. (2015). Role of adaptor protein MyD88 in TLR-mediated preconditioning and neuroprotection after acute excitotoxicity. Brain Behav. Immun. 46 221–231. 10.1016/j.bbi.2015.02.019 [PubMed] [CrossRef] [Google Scholar]
19. Li W., Suwanwela N. C., Patumraj S. (2016). Curcumin by down-regulating NF-kB and elevating Nrf2 reduces brain edema and neurological dysfunction after cerebral I/R. Microvasc. Res. 106 117–127. 10.1016/j.mvr.2015.12.008 [PubMed] [CrossRef] [Google Scholar]
20. Lo J. Y., Kamarudin M. N., Hamdi O. A., Awang K., Kadir H. A. (2015). Curcumenol isolated from Curcuma zedoaria suppresses Akt-mediated NF-kappaB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells. Food Funct. 6 3550–3559. 10.1039/c5fo00607d [PubMed] [CrossRef] [Google Scholar]
21. Ma Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. 53 401–426. 10.1146/annurev-pharmtox-011112-140320 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Mancuso C., Navarra P., Preziosi P. (2010). Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J. Neurochem. 113 563–575. 10.1111/j.1471-4159.2010.06606.x [PubMed] [CrossRef] [Google Scholar]
23. McDonald C. L., Hennessy E., Rubio-Araiz A., Keogh B., McCormack W., McGuirk P., et al. (2016). Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease. Brain Behav. Immun. 58 191–200. 10.1016/j.bbi.2016.07.143 [PubMed] [CrossRef] [Google Scholar]
24. Moss D. W., Bates T. E. (2001). Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur. J. Neurosci. 13 529–538. 10.1046/j.1460-9568.2001.01418.x [PubMed] [CrossRef] [Google Scholar]
25. Nakagawa Y., Chiba K. (2015). Diversity and plasticity of microglial cells in psychiatric and neurological disorders. Pharmacol. Ther. 154 21–35. 10.1016/j.pharmthera.2015.06.010 [PubMed] [CrossRef] [Google Scholar]
26. Neher J. J., Neniskyte U., Zhao J. W., Bal-Price A., Tolkovsky A. M., Brown G. C. (2011). Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J. Immunol. 186 4973–4983. 10.4049/jimmunol.1003600 [PubMed] [CrossRef] [Google Scholar]
27. Pae H. O., Jeong S. O., Kim H. S., Kim S. H., Song Y. S., Kim S. K., et al. (2008). Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-?B activation in RAW264.7 macrophages activated with LPS. Mol. Nutr. Food Res. 52 1082–1091. 10.1002/mnfr.200700333 [PubMed] [CrossRef] [Google Scholar]
28. Parada E., Buendia I., Navarro E., Avendano C., Egea J., Lopez M. G. (2015). Microglial HO-1 induction by curcumin provides antioxidant, antineuroinflammatory, and glioprotective effects. Mol. Nutr. Food Res. 59 1690–1700. 10.1002/mnfr.201500279 [PubMed] [CrossRef] [Google Scholar]
29. Park L. C., Zhang H., Gibson G. E. (2001). Co-culture with astrocytes or microglia protects metabolically impaired neurons. Mech. Ageing Dev. 123 21–27. 10.1016/S0047-6374(01)00336-0 [PubMed] [CrossRef] [Google Scholar]
30. Perry V. H., Holmes C. (2014). Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10 217–224. 10.1038/nrneurol.2014.38 [PubMed] [CrossRef] [Google Scholar]
31. Perry V. H., Nicoll J. A., Holmes C. (2010). Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6 193–201. 10.1038/nrneurol.2010.17 [PubMed] [CrossRef] [Google Scholar]
32. Prakobwong S., Khoontawad J., Yongvanit P., Pairojkul C., Hiraku Y., Sithithaworn P., et al. (2011). Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int. J. Cancer 129 88–100. 10.1002/ijc.25656 [PubMed] [CrossRef] [Google Scholar]
33. Rojo A. I., Innamorato N. G., Martin-Moreno A. M., De Ceballos M. L., Yamamoto M., Cuadrado A. (2010). Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson’s disease. Glia 58 588–598. 10.1002/glia.20947 [PubMed] [CrossRef] [Google Scholar]
34. Roodveldt C., Labrador-Garrido A., Gonzalez-Rey E., Lachaud C. C., Guilliams T., Fernandez-Montesinos R., et al. (2013). Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS One 8:e79160. 10.1371/journal.pone.0079160 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
35. Schipper H. M., Song W., Zukor H., Hascalovici J. R., Zeligman D. (2009). Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J. Neurochem. 110 469–485. 10.1111/j.1471-4159.2009.06160.x [PubMed] [CrossRef] [Google Scholar]
36. Spangenberg E. E., Green K. N. (2017). Inflammation in Alzheimer’s disease: lessons learned from microglia-depletion models. Brain Behav. Immun. 61 1–11. 10.1016/j.bbi.2016.07.003 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
37. Tsai Y. M., Chien C. F., Lin L. C., Tsai T. H. (2011). Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int. J. Pharm. 416 331–338. 10.1016/j.ijpharm.2011.06.030 [PubMed] [CrossRef] [Google Scholar]
38. Xia Q., Hu Q., Wang H., Yang H., Gao F., Ren H., et al. (2015). Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell. Death Dis. 6:e1702. 10.1038/cddis.2015.69 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
39. Yang S., Zhang D., Yang Z., Hu X., Qian S., Liu J., et al. (2008). Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem. Res. 33 2044–2053. 10.1007/s11064-008-9675-z [PubMed] [CrossRef] [Google Scholar]
40. Zhang J., Fu B., Zhang X., Zhang L., Bai X., Zhao X., et al. (2014). Bicyclol upregulates transcription factor Nrf2 HO-1 expression and protects rat brains against focal ischemia. Brain Res. Bull. 100 38–43. 10.1016/j.brainresbull.2013.11.001 [PubMed] [CrossRef] [Google Scholar]
41. Zhou J., Miao H., Li X., Hu Y., Sun H., Hou Y. (2017). Curcumin inhibits placental inflammation to ameliorate LPS-induced adverse pregnancy outcomes in mice via upregulation of phosphorylated Akt. Inflamm. Res. 66 177–185. 10.1007/s00011-016-1004-4 [PubMed] [CrossRef] [Google Scholar]
Sudden pain is a natural response of the nervous system which helps to demonstrate possible injury. By way of instance, pain signals travel from an injured region through the nerves and spinal cord to the brain. Pain is generally less severe as the injury heals, however, chronic pain is different than the average type of pain. With chronic pain, the human body will continue sending pain signals to the brain, regardless if the injury has healed. Chronic pain can last for several weeks to even several years. Chronic pain can tremendously affect a patient’s mobility and it can reduce flexibility, strength, and endurance.
Dr. Alex Jimenez utilizes a series of tests to help evaluate neurological diseases. The Neural ZoomerTM Plus is an array of neurological autoantibodies which offers specific antibody-to-antigen recognition. The Vibrant Neural ZoomerTM Plus is designed to assess an individual’s reactivity to 48 neurological antigens with connections to a variety of neurologically related diseases. The Vibrant Neural ZoomerTM Plus aims to reduce neurological conditions by empowering patients and physicians with a vital resource for early risk detection and an enhanced focus on personalized primary prevention.
XYMOGEN’s Exclusive Professional Formulas are available through select licensed health care professionals. The internet sale and discounting of XYMOGEN formulas are strictly prohibited.
Proudly, Dr. Alexander Jimenez makes XYMOGEN formulas available only to patients under our care.
Please call our office in order for us to assign a doctor consultation for immediate access.
If you are a patient of Injury Medical & Chiropractic Clinic, you may inquire about XYMOGEN by calling 915-850-0900.
* All of the above XYMOGEN policies remain strictly in force.
The information herein on "Functional Neurology: Curcumin for Brain Inflammation" is not intended to replace a one-on-one relationship with a qualified health care professional, licensed physician, and is not medical advice. We encourage you to make your own health care decisions based on your research and partnership with a qualified health care professional.
Our information scope is limited to chiropractic, musculoskeletal, physical medicines, wellness, sensitive health issues, functional medicine articles, topics, and discussions. We provide and present clinical collaboration with specialists from a wide array of disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for the injuries or disorders of the musculoskeletal system.
Our videos, posts, topics, subjects, and insights cover clinical matters, issues, and topics that relate to and support, directly or indirectly, our clinical scope of practice.*
Our office has made a reasonable attempt to provide supportive citations and has identified the relevant research study or studies supporting our posts. We provide copies of supporting research studies available to regulatory boards and the public upon request.
We understand that we cover matters that require an additional explanation of how it may assist in a particular care plan or treatment protocol; therefore, to further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez or contact us at 915-850-0900.
We are here to help you and your family.
Dr. Alex Jimenez DC, MSACP, CIFM*, IFMCP*, ATN*, CCST
My Digital Business Card
Prescription Medications: Sciatica is a term used to describe neuropathic/nerve pain. It is a prevalent… Read More
Introduction The sciatic nerve is considered the largest in the lower half of the body that helps… Read More
Introduction Inside the body are countless nerves that intertwine with each other and are all… Read More